Schrodinger (SDGR) said Monday it received an additional $9.5 million from the Bill & Melinda Gates Foundation to accelerate its initiative to expand its computational platform for early toxicology risk prediction in drug discovery.
The additional funding, which follows the initial $10 million grant from the foundation in July, enables Schrodinger to access relevant experimental structures faster and extends the funding for the initiative to April 2026, Schrodinger said.
The company said the initiative aims to reduce development failures and improve drug safety, and once developed, the technology will be available to Gates Foundation grantees and Schrodinger's customers.
The majority of revenue related to the additional funding is anticipated to be recognized next year, the company said.
Schrodinger shares were down more than 5% in recent Monday trading.
Price: 17.55, Change: -0.99, Percent Change: -5.34
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。